T2 Biosystems, Inc.

TTOO

US89853L3024

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-17 EDT			5-day change	1st Jan Change
5.64 ^USD	0.00%		+52.64%	-10.12%

05-15	Sector Update: Health Care Stocks Advance Late Wednesday Afternoon	MT
05-15	T2 Biosystems Shares Rise After CRG Servicing Ups Stake	MT

T2 Biosystems, Inc. Provides Revenue Guidance for the 2021

August 05, 2021 at 04:05 pm

T2 Biosystems, Inc. provided revenue guidance for the 2021. For the year, the company expected revenue to be between $24.0 million and $26.0 million.

Latest news about T2 Biosystems, Inc.

Sector Update: Health Care Stocks Advance Late Wednesday Afternoon	05-15	MT
T2 Biosystems Shares Rise After CRG Servicing Ups Stake	05-15	MT
Top Midday Gainers	05-15	MT
T2 Biosystems, Inc. announced that it expects to receive $8.000002 million in funding	05-14	CI
T2 Biosystems Announces Letter of Intent to Enter Strategic Partnership for Lyme Disease	05-07	CI
North American Morning Briefing : Stock Futures Muted After Rally Fueled by Rate-Cut Hopes	05-07	DJ
T2 Biosystems, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-06	CI
Earnings Flash (TTOO) T2 BIOSYSTEMS Posts Q1 Revenue $2.1M	05-06	MT
T2 Biosystems, Inc. Reiterates Revenue Guidance for the Full Year 2024	05-06	CI
T2 Biosystems, Inc. Announces Commercial Expansion Through Middle East Distributor	05-06	CI
Transcript : T2 Biosystems, Inc., Q1 2024 Earnings Call, May 06, 2024	05-06
Canaccord Genuity Adjusts Price Target on T2 Biosystems to $3 From $12, Maintains Hold Rating	04-29	MT
Top Premarket Decliners	04-23	MT
T2 Biosystems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc	03-28	CI
T2 Biosystems, Inc. Reiterates Revenue Guidance for the Year 2024	03-20	CI
Transcript : T2 Biosystems, Inc. - Special Call	03-20
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates	03-20	CI
T2 Biosystems, Inc. Announces Publication of New Study Highlighting Clinical Benefits and Performance of Real-World Use of T2Resistance Panel in Journal of Clinical Microbiology	03-18	CI
Transcript : T2 Biosystems, Inc., Q4 2023 Earnings Call, Feb 15, 2024	02-15
T2 Biosystems, Inc. Announces Commercial Expansion Through Distributors in Europe and Asia	02-15	CI
Sector Update: Health Care Stocks Mixed Late Afternoon	02-12	MT
Sector Update: Health Care Stocks Steady in Afternoon Trading	02-12	MT
T2 Biosystems Gets FDA Clearance for Expanded T2Bacteria Panel; Shares Rise	02-12	MT
T2 Biosystems Gets 510(k) Clearance For Expanded T2Bacteria Panel	02-12	DJ

T2 Biosystems, Inc. is an in vitro diagnostics company focused on the detection of sepsis-causing pathogens and antibiotic resistance genes. Its technology enables detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its focus includes three areas: sepsis, bioterrorism, and Lyme disease. The Company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the T2 Magnetic Resonance (T2MR) technology. It also has an active pipeline of products, including the United States T2Resistance Panel, the Candida auris test, and the T2Lyme Panel. T2Dx Instrument is a fully automated instrument that is capable of running a range of diagnostic tests from patient samples.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-07-30 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

5.64 USD

Average target price

3 USD

Spread / Average Target

-46.81%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
T2 BIOSYSTEMS, INC.	-10.12%	86.66M
THERMO FISHER SCIENTIFIC	+12.15%	227B
DANAHER CORPORATION	+14.90%	197B
INTUITIVE SURGICAL, INC.	+18.22%	141B
BOSTON SCIENTIFIC CORPORATION	+29.15%	110B
SIEMENS HEALTHINEERS AG	+1.56%	64.15B
EDWARDS LIFESCIENCES CORPORATION	+16.92%	53.72B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+6.33%	51.75B
AGILENT TECHNOLOGIES, INC.	+10.93%	45.2B
GE HEALTHCARE TECHNOLOGIES INC.	+5.87%	37.37B

Other Advanced Medical Equipment & Technology